skip to Main Content

Company Profile

About Company Profile illustration
Company Profile

We are a clinical-stage bio­phar­ma­ceu­tical company focused on the devel­opment of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH (Non-alco­holic Steato­hep­atitis) for variable pop­u­la­tions, as well as other liver asso­ciated dis­orders.

We believe that our product can­didate, Aramchol, has the potential to be a disease mod­i­fying treatment for fatty liver dis­orders, including NASH, which is a chronic disease that con­sti­tutes a large unmet medical need.

Galmed’s business has been oper­ating since 2000 under a dif­ferent group of com­panies estab­lished in the same year. Galmed Phar­ma­ceu­ticals Ltd. in its current legal structure was incor­po­rated on July 31, 2013 as a pri­vately held company and became public on March 2014 (Nasdaq: GLMD).

Back To Top